B-Cell Level May Affect COVID Booster Efficacy in MS

A B-cell count of at least 40/µL is necessary to mount an adequate antibody response to COVID-19 boosters in patients with multiple sclerosis, new research shows.

Related Keywords

Sweden ,United States ,Ohio ,Uppsala ,Uppsala Lan ,Cleveland ,Robertj Fox ,Joachim Burman ,Uppsala University ,Pfizer ,Neurological Institute At Cleveland Clinic ,Mellen Center ,Medscape Coronavirus Resource Center ,Uppsala University Hospital ,Coronavirus Resource ,Medscape Medical ,Neurological Institute ,Cleveland Clinic ,Multiple Sclerosis Ms ,Multiple Sclerosis ,Us ,Vaccine ,Covid 19 Vaccine ,Coronavirus Vaccine ,Biologic Therapy ,Monoclonal Antibody ,Etuximab ,Ituximab ,Coronavirus ,019 Novel Coronavirus ,019 Ncov ,Uhan Coronavirus ,Uman Coronavirus Hku1 ,Uman Coronavirus Oc43 ,Cov Oc43 ,Uman Coronavirus 229e ,Cov 229e ,Clinical Guidelines ,Guidelines ,Generics ,Generic Drug ,Eneric Medication ,Hospitals ,Hi ,